McKesson Change in Accounts Receivable 2010-2025 | MCK
McKesson annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- McKesson change in accounts receivable for the quarter ending June 30, 2025 was $-2.089B, a 0.57% decline year-over-year.
- McKesson change in accounts receivable for the twelve months ending June 30, 2025 was $-13.587B, a 8.18% increase year-over-year.
- McKesson annual change in accounts receivable for 2025 was $-3.935B, a 33.21% increase from 2024.
- McKesson annual change in accounts receivable for 2024 was $-2.954B, a 173.01% increase from 2023.
- McKesson annual change in accounts receivable for 2023 was $-1.082B, a 41.29% decline from 2022.
McKesson Annual Change in Accounts Receivable
(Millions of US $) |
| 2025 |
$-3,935 |
| 2024 |
$-2,954 |
| 2023 |
$-1,082 |
| 2022 |
$-1,843 |
| 2021 |
$1,145 |
| 2020 |
$-2,494 |
| 2019 |
$-967 |
| 2018 |
$1,175 |
| 2017 |
$-762 |
| 2016 |
$-1,957 |
| 2015 |
$-2,821 |
| 2014 |
$-868 |
| 2013 |
$318 |
| 2012 |
$-768 |
| 2011 |
$-673 |
| 2010 |
$-133 |
| 2009 |
$-708 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$85.018B |
$359.051B |
|
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
|
